Nvidia invests in Generate Biomedicines, targeting $1.8T market with AI-driven drug discovery

Nvidia’s venture arm, NVentures, disclosed ownership of 833,325 shares in Generate:Biomedicines, valued at approximately $10.4 million according to Nvidia’s latest 13F filing in May 2026. Generate, which trades on the Nasdaq under the ticker GENB, is building an AI-powered platform designed to automate the generation and optimization of therapeutic proteins, essentially trying to compress years of drug discovery into months.

What Generate:Biomedicines actually does

The company uses generative AI models to design proteins and drug candidates from scratch. Generate’s pipeline is already well past the theoretical stage. The company has a Phase 3 clinical trial underway for severe asthma, which is the final stage of testing before seeking regulatory approval. It also has multiple oncology candidates that have received FDA Fast Track designation, a status reserved for treatments addressing serious conditions with unmet medical needs.

The company has raised roughly $700 million in total funding since its founding. NVentures first got involved during Generate’s $273 million Series C round, which closed in September 2023 and included participation from Amgen, one of the world’s largest biotech companies. Generate then went public with a Nasdaq IPO in February 2026.

Why Nvidia cares about drug design

A $10.4 million stake is pocket change for a company of Nvidia’s size. But by investing in companies like Generate, Nvidia is seeding an ecosystem of customers who will need its chips for decades to come. Drug discovery fits that description: simulating how proteins fold, predicting how molecules will interact with human biology, and running thousands of virtual experiments simultaneously all demand the kind of parallel processing that Nvidia’s hardware was built for.

What this means for investors watching crypto and AI

The risk profile here is worth considering. Generate:Biomedicines is still a clinical-stage company, meaning it hasn’t generated significant revenue from approved products yet. Phase 3 trials can and do fail, and even Fast Track designation doesn’t guarantee approval. The approximately $700 million in funding the company has raised will need to carry it through what could be years of additional clinical work.

For investors holding positions in Nvidia or adjacent AI infrastructure plays, Generate’s progress through clinical trials is now a data point worth tracking. A successful Phase 3 readout for the severe asthma program wouldn’t just move GENB. It would strengthen the thesis that AI-driven compute is becoming indispensable in industries far beyond tech, which is ultimately the bull case for Nvidia itself.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.